title: The low dose (7.5mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure.
authors.affiliation: Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Adachi
authors.affiliation: Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan.
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Katsuyama
authors.affiliation: Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan; Clinical Research Center, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan. Electronic address: dyanai@hospk.ncgm.go.jp.
authors.forename: Hidekatsu
authors.initials: H
authors.lastname: Yanai
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000209:etiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D000077205:Pioglitazone; D012189:Retrospective Studies; D045162:Thiazolidinediones / Q000627:therapeutic use*; D015430:Weight Gain
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D020097:Natriuretic Peptide, Brain; D000077205:Pioglitazone
keywords: B-type natriuretic peptide; Body weight gain; Heart Failure; Pioglitazone